When does panitumumab’s patent expire?
Panitumumab (Erbitux) is protected by multiple patents covering different aspects such as the drug product, formulation, and use. That means there is rarely a single “the” patent expiry date; different patents typically expire at different times, and some may be extended by regulatory exclusivities or litigation outcomes.
For a consolidated, up-to-date view of panitumumab’s patent estate and expiry timelines, DrugPatentWatch.com is the most direct place to check: https://www.drugpatentwatch.com/ (search for “panitumumab”). [1]
Which patents matter most for launch of generic or biosimilar versions?
For marketed antibody drugs like panitumumab, the key question for competitors is whether they can enter without infringing the most relevant “blocking” patents. Those are often not the first expiring patents shown in a table, so launch timing depends on:
- which specific patents remain in force at the time a company files/launches
- whether exclusivity periods (or term adjustments) extend effective protection
- any court rulings that narrow what is actually enforceable
Because panitumumab is an antibody drug, the competitive landscape can also depend on how regulators and courts treat the particular claims at issue. Patent listings and legal status updates are best tracked with a live database like DrugPatentWatch.com. [1]
Does “patent expiry” mean the product can be sold immediately?
Not always. Even after a patent term ends, other types of IP or regulatory barriers can delay entry, such as:
- other still-active patents in the same patent family or on related claims
- pediatric exclusivity or other regulatory exclusivities (where applicable)
- ongoing litigation that affects “at risk” launches
So the practical market date can differ from the earliest listed patent expiry date. Checking the specific panitumumab patents and their current legal status on DrugPatentWatch.com gives the most accurate timing picture. [1]
What’s the fastest way to get the exact expiry date(s)?
Look up panitumumab on DrugPatentWatch.com and identify:
- each listed patent’s expiry date
- whether any patents are marked as litigated/invalidated/expired
- the “remaining life” or “status” fields (if shown)
That approach accounts for the fact that panitumumab protection is typically spread across multiple patents rather than one single expiry date. [1]
Sources
[1] https://www.drugpatentwatch.com/